Explore the frontier
Filter every story, video, company, game and lab experiment by topic, disease area, technology, company, development stage, format and audience.
6 results · 2 filters activeClear all
NewLimit
Not publicly tradedNewLimit develops epigenetic reprogramming medicines intended to restore youthful function to aged cells, starting with liver cells. It was co-founded by Brian…
Altos Labs
Not publicly tradedAltos Labs studies cellular rejuvenation — resetting aspects of cell state to restore health and resilience. It has research sites in the…
Retro Biosciences
Not publicly tradedRetro Biosciences aims to extend healthy human lifespan through programs in autophagy, cell replacement and tissue reprogramming. Its lead oral drug, RTR242,…
LongevityThe Cell Health Frontier: Senescence, Mitochondria, and the Search for Better Healthspan
Some problems of ageing may start inside individual cells. This explainer tours senescence and mitochondria, from striking mouse results to small, mixed human trials, and explains why no therapy is yet approved to treat ageing.
LongevityCan We Slow Aging? A Field Guide to Evidence, Hype, and Hard Questions
Longevity claims are everywhere, but human evidence is thin. This field guide sorts the most popular anti-ageing ideas by what has been shown in animals, what has been tested in people, and what nobody knows yet.
LongevityThe Longevity Dashboard: Which Health Measures Are Useful, and Which Are Still Experimental?
Some longevity metrics, like blood pressure, are backed by decades of evidence and clear actions. Others, like consumer biological-age tests, are promising research tools whose meaning for individuals is not yet settled.